Advisers behind the proposed $4bn (€4.53bn) merger of Shire Pharmaceuticals of the UK and Canada's BioChem Pharma have cleared the final hurdle to collecting their fees.

The companies agreed to merge on December 11 last year, and the deal was due to complete on March 30. However, completion was delayed because the Canadian minister of industry, responsible for the Investment Canada Act, extended the merger review period.